• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Pfizer's Xalkori picks up FDA nod for rare ALK-positive tumors

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 15, 2022 at 11:12: AM
via First endorsed 11 years ago for anaplastic lymphoma kinase (ALK)-positive lung cancer, Pfizer’s Xalkori is being surpassed in that indication by the company’s own Lorbrena and Takeda’s Alunbrig.

article source
 

<



Similar threads

cafead
Pfizer&#039;s Lorbrena makes play for earlier lung cancer use with Xalkori-topping data
Replies
0
Views
177
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA Grants Pfizer&#039;s Xalkori Breakthrough Therapy Status for Two New Indications
Replies
0
Views
146
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AstraZeneca steps out from Daiichi&#039;s shadow, posting data on in-house rivals to AbbVie and Pfizer ADCs
Replies
0
Views
12
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Vaxcyte&#039;s &#039;stunning&#039; 31-valent pneumococcal vaccine win against Pfizer&#039;s Prevnar 20 has analysts thinking big
Replies
0
Views
19
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Pfizer, BioNTech&#039;s combo mRNA shot is latest to be defeated by influenza strain B
Replies
0
Views
11
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote